Form 4: Decheng Capital Funds Report Beneficial Ownership Changes in Aardvark Therapeutics Following IPO

Decheng Capital Global Life Sciences Fund IV, L.P. and related entities report changes in beneficial ownership of Aardvark Therapeutics common stock and convertible preferred stock following the company's IPO.

Summary

• Decheng Capital Global Life Sciences Fund IV, L.P. and related entities, including Decheng Capital Management IV (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, and Xiangmin Cui, filed a Form 4 detailing changes in their beneficial ownership of Aardvark Therapeutics, Inc. [AARD] securities.
• The filing reports transactions occurring on February 14, 2025, related to the conversion of Series C Convertible Preferred Stock into common stock immediately prior to Aardvark Therapeutics' IPO.
• Decheng Capital Global Life Sciences Fund IV, L.P. acquired 2,333,887 shares of common stock through the conversion of Series C Convertible Preferred Stock and an additional 625,000 shares through open market purchases at $16 per share, resulting in a total beneficial ownership of 2,958,887 shares.
• Decheng Capital Global Healthcare Fund (Master), LP acquired 333,412 shares of common stock through the conversion of Series C Convertible Preferred Stock and an additional 625,000 shares through open market purchases at $16 per share, resulting in a total beneficial ownership of 958,412 shares.
• The Series C Convertible Preferred Stock converted at a ratio of 8.474-for-1 into common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document is a standard regulatory filing detailing changes in ownership following an IPO. The open market purchases at $16 per share are a positive sign.

Positives

• The document indicates continued investment in Aardvark Therapeutics by Decheng Capital through open market purchases at $16 per share.

Industry Context

Form 4 filings are standard practice following significant transactions, such as an IPO, that alter the ownership structure of a publicly traded company. This filing provides transparency into the holdings of major shareholders.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for insiders and major shareholders of publicly traded companies in the United States.
• Similar filings are made by venture capital and private equity firms following IPOs of their portfolio companies to disclose changes in ownership positions.
• The level of detail provided in this Form 4 is consistent with industry norms for such filings.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of Aardvark Therapeutics following its IPO.
• The reported transactions may influence investor perception of the company's stock.

Key Dates